Source The Lancet. Oncology, ISSN: 1474-5488, Vol: 20, Issue: 8, Page: e443-e451 Chimeric antigen receptor (CAR) T-cell therapy is one of the most remarkable advances in cancer therapy in the last several decades. More than 300 adoptive T-cell therapy trials are ongoing, which is a testament to the early success and hope engendered by this
New research has observed that the benefits of CAR-T cell immunotherapies – for the treatment of diseases such as pediatric acute lymphoblastic leukemia and diffuse large B-cell lymphoma – may be offset by their delayed delivery to patients. The social value of a therapy balances manufacturer costs and profits versus a patient’s improvement in quality-adjusted
Decision ensures consistency in access to the innovative new cancer therapy, and CMS is working closely with sister agencies to monitor outcomes for patients receiving the therapy Today the Centers for Medicare & Medicaid Services (CMS), under the leadership of President Trump and Secretary Azar, finalized the decision to cover FDA-approved Chimeric Antigen Receptor T-cell, or “CAR
The first agreement (with Novartis) for therapies that allow to reprogram some cells of the patient (the T lymphocytes), in order to make them able, once reinfused, to recognize and target the tumors, is approved by the CPR and CTS of Aifa. Now the agreement will have to be ratified by the AIFA Board and
Transporting irreplaceable products means having trust in the technology Cell and gene therapies could be flying high soon, joining the medical supplies, whole blood products, and even organs being transported by drones. In collaboration with RPS Aerospace, the Italy-based biotech company Anemocyte developed a remotely piloted drone system to securely transport final cell and gene
Novel automation technologies enable the decentralized manufacturing of highly standardized CAR-T cell products in academic GMP facilities experienced with the production of patient-individual cell therapies. Dr Janet Rossig discusses the benefits of academic cell manufacturing, namely supporting the informed dissemination of CAR-T cell therapy to patients who benefit from this modality. She argues that this
Source NIH Researchers continue to make progress with cancer immunotherapy, a type of treatment that harnesses the body’s own immune cells to attack cancer. But Kole Roybal wants to help move the field further ahead by engineering patients’ immune cells to detect an even broader range of cancers and then launch customized attacks against them.
Source PMLive Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking CAR-T therapy for the first patient in Europe, and how the centre of excellence has adapted to make precision medicine a reality Dr
Many of the efforts to improve on the first generation of CAR-T therapies such that they can reach solid tumors had focused on tweaks inherent to the cancer killing agent — specifically, utilizing more potent T cells as their base, from stem memory T cells to virally associated T cells to marrow infiltrating lymphocytes. But
Article Highlights CAR T-cell therapy is gaining traction in relapsed/refractory lymphoma in older patients with aggressive disease. As a result of prospective trials investigating CAR T-cell therapy, there is potential that older patients with lymphoma can be spared multiple lines of chemotherapy and its resultant toxicities while still having long-term clinical benefit. Toxicities are still
